Related Articles
Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer
Phase II study of palliative S-1 in combination with cisplatin as second-line chemotherapy for gemcitabine‑refractory pancreatic cancer patients
Disease-adapted relapse therapy for ovarian cancer: results of a prospective study.
Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer
Serum CA125 assay in the early diagnosis of recurrent epithelial ovarian cancer